강스템바이오텍, 오가노이드 첫 고객사 내방…반복매출화 검증대

Kangstembiotech's heavy CDMO dependency (71% of Q1 revenue) makes the organoid business's shift toward recurring revenue models critical for the company's future sustainability. The pharma customer's facility inspection signals a serious step toward commercialization beyond one-time research contracts. Success in recurring drug screening and organoid supply partnerships would fundamentally diversify the company's revenue structure and reduce reliance on volatile CDMO services.